BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/5/2025 6:36:20 AM | Browse: 783 | Download: 594
 |
Received |
|
2025-05-28 15:20 |
 |
Peer-Review Started |
|
2025-05-28 15:20 |
 |
First Decision by Editorial Office Director |
|
2025-06-11 07:39 |
 |
Return for Revision |
|
2025-06-11 07:39 |
 |
Revised |
|
2025-06-21 15:28 |
 |
Publication Fee Transferred |
|
|
 |
Editorial Processing by Scientific Editor |
|
2025-08-18 02:35 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2025-08-18 06:00 |
 |
Articles in Press |
|
2025-08-18 06:00 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2025-08-25 06:39 |
 |
Publish the Manuscript Online |
|
2025-09-05 06:36 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Natural killer cell-based immunotherapies for colorectal cancer: Current strategies, challenges, and future perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xiao-Jun Zhang, Yan Yu, Jing-Yu Li, Yu-Zhu Yan, Sha-Sha Jiang, Yi Zhang, Qin Fei, Yi-Ran Zhang, Yong-Xin Zhao, Lei Guo, Jing Lv and He-Ping Zhao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Shaanxi Natural Science Foundation of China |
2025JC-YBMS-916 |
| Xi’an Municipal Health Commission of China |
2023ms11 |
|
| Corresponding Author |
Jing Lv, MD, Department of Clinical Laboratory, Honghui Hospital, Xi’an Jiaotong University, No. 555 Youyi East Road, Xi’an 710054, Shaanxi Province, China. lvjing-1219@163.com |
| Key Words |
Natural killer cells; Colorectal cancer; Immunotherapy; Immunosuppression; Tumor microenvironment |
| Core Tip |
Natural killer (NK) cell-based immunotherapy represents a breakthrough approach for treating colorectal cancer (CRC), particularly for microsatellite-stable tumors resistant to conventional treatments. Currently employed strategies, including cytokine therapy, checkpoint inhibition, and chimeric antigen receptor-NK cell therapy, show promise in CRC treatment, but manufacturing challenges and the immunosuppressive tumor microenvironment limit their efficacy. Emerging solutions combining gene-editing, nanotechnology, and personalized approaches may overcome these barriers, positioning NK cell therapy as a transformative CRC treatment modality. |
| Publish Date |
2025-09-05 06:36 |
| Citation |
Zhang XJ, Yu Y, Li JY, Yan YZ, Jiang SS, Zhang Y, Fei Q, Zhang YR, Zhao YX, Guo L, Lv J, Zhao HP. Natural killer cell-based immunotherapies for colorectal cancer: Current strategies, challenges, and future perspectives. World J Gastroenterol 2025; 31(34): 110051
|
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i34/110051.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i34.110051 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.